CClinicalTrials.gg
CompletedNCT03990012Updated Aug 2, 2022

Infrared Imaging for Breast Cancer Modeling

An interventional study of IR Imaging and 3D Scanning in Breast Cancer, sponsored by University of Texas Southwestern Medical Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-02.

Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The primary objective of this study is to obtain infrared (IR) images and video and three-dimensional (3-D) scans of patients referred for biopsy based on the results of their diagnostic breast exam(s).

This research study is investigating infrared imaging (also referred to as infrared thermography, or digital infrared thermal imaging (DITI)) of breast cancer. The infrared images collected in this study will be used to construct a computational biothermal engineering model of the cancerous breast.

Patients will undergo standard breast cancer screening procedures as part of routine care at Parkland Comprehensive Breast Center. For any patients who are referred for biopsy based on the results of their breast cancer screening procedures, this research study will take infrared images of the patient. Patients will undergo infrared imaging prior to biopsy but will not delay biopsy or treatment; infrared images \& video may be recorded at biopsy visit. The biopsy will confirm/diagnose whether the patient has a benign or malignant condition.

Read the detailed description

The purpose of this research study is to obtain IR images, IR video, and 3-D scans of female patients' breasts (i.e., thermograms) who have been referred for biopsy based on the results of their diagnostic breast exams. These patients may be later diagnosed with a malignant or benign breast condition. The infrared images and video collected will be used to construct and validate a computational biothermal engineering model of breast cancer.

This research study does not involve any investigational drugs or treatments. This research study does not involve any FDA-approved drugs or devices.

In this research study, the equipment used (IR camera, 3-D scanner) will no be tested nor be used to diagnose or treat. Further, medical decisions will not be based on the use of these devices.

Infrared imaging (or digital thermal infrared imaging, DITI) is a non-invasive, non-contact, and harmless imaging procedure that measures the natural infrared radiation (body heat) emitted by the human body at normal 37°C body temperature. This procedure does not expose the patient to any radiation and is therefore entirely safe for the patient.

IR images and video will be obtained by IR equipment provided by University of Texas (UT) at Dallas researchers. IR equipment consists of an IR camera and ancillary equipment (e.g., tripod, computer, and vendor-provided IR image-processing software). The IR camera that will be used will be a commercial off-the-shelf product.

Additionally, a 3-D scanner will be used to obtain a 3-D surface contour map of the patient's breasts. This 3-D scanner is also non-invasive, non-contact, and does not expose the patient any radiation, similar to the IR camera. The 3-D scanner outputs a file format that is compatible with 3-D computer-aided design (CAD) software for engineering analysis.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 11 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

University of Texas Southwestern Medical Center is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 135 completed or terminated interventional studies of FDA-regulated products, 100 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Females with a suspicious breast mass (BI-RADS 4C or 5).
  • Referred for a breast biopsy.
  • Capable of providing informed consent.

Exclusion criteria

Exclusion Criteria:

  • Currently undergoing treatment for breast cancer.
  • Incapable of providing informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Patients referred for breast biopsy

    Patients with Breast Imaging-Reporting and Data System (BI-RADS) 4C or 5 diagnosis who have been referred for breast biopsy based on the results of their standard diagnostic breast exam will undergo IR and 3D imaging of the breasts.

    Procedure: IR Imaging · Procedure: 3D Scanning

Interventions

  • ProcedureIR Imaging

    Subjects will undergo steady steady state and video IR imaging of the breasts.

  • Procedure3D Scanning

    Subjects will undergo 3D scanning of the breasts.

06

What researchers measure

Primary outcomes

  1. Spatial location of breast tumors

    Researchers will use subjects' radiological imaging data to quantify the location of the tumor inside the breast, including mammography, ultrasound, and/or magnetic resonance imaging (MRI), for patients who are diagnosed with breast cancer. The tumor location will be measured. The tumor location will serve as an input for the computational model. No diagnostic assessments will be made from these data for this research study.

    Time frame: Two years

  2. 3-D Surface contour maps of the breast

    Researchers will use a 3-D scanning device to reconstruct the 3-D surface geometry of subjects' breasts. The surface geometry of subjects' breasts will be measured. The surface geometry will serve as an input for the computational model. No diagnostic assessments will be made from these data for this research study.

    Time frame: Two years

  3. Computational thermal model of breast cancer

    Researchers will use study data to validate a computational biothermal engineering model of the cancerous breast. The computational model will model and simulate the internal thermodynamic and heat transfer processes inside the breast with cancer. The model outputs expected surface temperatures of the breast with cancer. The model will be constructed using commercial engineering software, ANSYS Fluent. No diagnostic assessments will be made from these data for this research study.

    Time frame: Two years

07

Study locations

1 site
  • Parkland Memorial Hospital
    Dallas, Texas 75235, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03990012
Lead sponsor
University of Texas Southwestern Medical Center
Responsible party
Jody Hayes (Assistant Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Jun 18, 2019
Start date
Jun 13, 2019
Primary completion
Dec 15, 2021
Completion
Jun 1, 2022
Last update
Aug 2, 2022

Study contacts

Jody Hayes, MD
principal investigator · UT Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion